ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 772

RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic Gene Expression Subsets Shows Differential Expression of Non-Coding RNAs Regulating SSc Gene Expression

Zhenghui Li1, Eleni Marmarelis2, Kun Qu3, Lionel Brooks4, Patricia Pioli4, Howard Chang3, Robert Lafyatis5 and Michael Whitfield4, 1Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 3Stanford University School of Medicine, Stanford, CA, 4Geisel School of Medicine at Dartmouth, Hanover, NH, 5Arthritis Center, Boston University, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Gene Expression, genomics, MicroRNA, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Systemic sclerosis (SSc) is an autoimmune disease with a heterogenous and complex phenotype. Previously, our lab has identified four gene expression subsets (fibroproliferative, inflammatory, limited and normal-like) among SSc patients by their gene expression in skin using DNA microarrays. We have extended these findings by using RNA-Seq in a subset of SSc skin biopsies to detect mRNA levels, splice variants, novel non-coding RNAs, and coding region SNPs in a lower background signal over microarray. 

Methods: We performed RNA-Seq on eight SSc patients and four healthy controls and skin biopsies. The eight SSc patients included five individuals that mapped to the inflammatory subset and three from the fibroproliferative subset. We sequenced the small and large RNA fraction extracted from each biopsy by Illumina Solexa sequencing. We obtained 90-100 million 50 bp paired-end reads for the mRNA fraction and 25 – 50 million 36 bp reads for the miRNA fraction. 

Results:   Our analyses reveal significant (p<0.05) gene expression differences between healthy controls and SSc patients, as well as between intrinsic subsets. Specifically, we found >1000 genes are significantly expressed in the inflammatory and the fiboproliferative subsets of patients. Many of the significant genes are involved in cellular proliferation or immune responses, consistent with results found by DNA microarray hybridization. We did not observe any significant differential splicing between the healthy controls and the SSc patients. We identified 228 novel long non-coding RNAs (lncRNAs) that are significantly differentially expressed in the inflammatory subset and fibroproliferative subsets. The lncRNAs differentially expressed in the inflammatory subset map to Gene Ontology terms including inflammatory response, immune response, response to wounding, and defense response and those in the fibroproliferative group map to cell cycle, M phase, and RNA metabolism.  We also identified 54 miRs differentially expressed in the inflammatory subset of SSc patients.  These include the well-characterized miR21 that has previously been reported to be differentially expressed in SSc as well as many novel miRs.  We have previously shown CCL2 to be highly expressed in the inflammatory subset of SSc and inhibiting its function prevents development of disease in the sclGVHD mouse model.  We now identify a novel miR with decreased expression that is predicted to target the 3’UTR of CCL2.  We show that transfection of the CCL2-targeting miR, but not a negative control miR, into RAW264.7 macrophage cells expressing a heterologous Luciferase-CCL2 (3’UTR) reduced luciferase activity by 74%.

Conclusion:   To summarize, we conducted the first comprehensive RNA-Seq study in SSc skin and identified differentially expressed non-coding RNAs genome-wide.  Our findings show that a complex network of regulatory factors controls the disease specific gene expression subsets in SSc skin.


Disclosure:

Z. Li,
None;

E. Marmarelis,
None;

K. Qu,
None;

L. Brooks,
None;

P. Pioli,
None;

H. Chang,
None;

R. Lafyatis,
None;

M. Whitfield,

Celdara, LLC,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rna-seq-and-mir-seq-analysis-of-ssc-skin-across-intrinsic-gene-expression-subsets-shows-differential-expression-of-non-coding-rnas-regulating-ssc-gene-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology